SHPH
Shuttle Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.50
+0.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 922.4K | — | — | — | 6.0K |
| Gross Profit | (922.4K) | — | — | — | (6.0K) |
| Operating Expenses | |||||
| R&D Expense | 2.7M | 4.1M | 3.6M | 3.5M | 1.0M |
| SG&A Expense | 7.6M | 7.9M | 4.1M | 2.4M | 1.3M |
| General & Admin Expense | 7.6M | 7.9M | 4.1M | 2.4M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (133.4K) | — | — | — | — |
| Total Operating Expenses | 10.3M | 11.9M | 7.7M | 5.9M | 2.3M |
| Cost and Expenses | 11.2M | 11.9M | 7.7M | 5.9M | 2.3M |
| Operating Income (EBIT) | (11.2M) | (11.9M) | (7.7M) | (5.9M) | (2.3M) |
| Non-Operating | |||||
| Interest Income | 1.3K | 1.1K | 38.1K | 79.1K | — |
| Interest Expense | 71.0K | 70.8K | 1.4M | 2.6M | 670.6K |
| Net Interest Income | (69.7K) | (69.7K) | (1.3M) | (2.5M) | (670.6K) |
| Other Non-Op Income/Expense | 361.3K | 195.2K | (1.4M) | (700.3K) | (2.7M) |
| Non-Operating Income (excl Interest) | (432.3K) | (266.0K) | 88.5K | (1.9M) | 2.0M |
| EBT (Pre-Tax Income) | (10.8M) | (11.7M) | (9.1M) | (6.6M) | (5.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.8M) | (11.7M) | (9.1M) | (6.6M) | (5.0M) |
| Earnings from Cont. Ops | (10.8M) | (11.7M) | (9.1M) | (6.6M) | (5.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.8M) | (11.7M) | (9.1M) | (6.6M) | (6.7M) |
| Per Share | |||||
| Basic EPS | ($60.60) | ($71.60) | ($8,857.30) | ($4.10) | ($3.00) |
| Diluted EPS | ($60.60) | ($71.60) | ($8,857.30) | ($4.10) | ($3.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 503156 | 163792 | 1.0M | 1.6M | 1.0M |
| Diluted Shares Outstanding | 503156 | 163792 | 1.0M | 1.6M | 1.0M |
| Profitability Metrics | |||||
| EBITDA | (9.8M) | (11.4M) | (7.8M) | (4.0M) | (4.3M) |
| D&A | 923.4K | 290.1K | 5.5K | 6.8K | 6.0K |
| EBIT | (10.8M) | (11.7M) | (7.8M) | (4.0M) | (4.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026